Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Last year, Keytruda generated ... approved a $30.2 million grant to Merck, contingent on the company’s decision to set up operations at the Chestnut Run Innovation & Science Park (CRISP ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

A groundbreaking ceremony was held at Chestnut Run Innovation & Science Park on April 29, bringing together business and government officials to celebrate the milestone. Merck’s facility ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The site will also have the capability to manufacture KEYTRUDA ® (pembrolizumab), and ... Davis, chairman and chief executive officer, Merck. The new facility, located at Chestnut Run Innovation & ...

A groundbreaking ceremony was held at Chestnut Run Innovation & Science Park on April 29, bringing together business and government officials to celebrate the milestone. Merck’s facility ...